Pyrrolizidine

DB19159InvestigationalSmall molecule

Pyrrolizidine is under investigation in clinical trial NCT05898373 (Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC).

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
Curator reviewed
Formula / weight: C₇H₁₃N · 111.188 g/mol (avg)
Also known as: 1-azabicyclo(3.3.0)octane · 1h-pyrrolizine, hexahydro- · Hexahydropyrrolizine
Code names: NSC-145060 · NSC-90874

Resolves to

Compound

UNIIU81KWZ2JKNCAS643-20-9ChEBI64950

Structure

InChIKeyADRDEXBBJTUCND-UHFFFAOYSA-NSMILESC1CC2CCCN2C1

Targets

P04626ERBB2

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Pyrrolizidine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account